UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Abstract

A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in patients with locally advanced non-small-cell lung cancer. Eligible patients with cytologically or histologically confirmed, unresectable stage III non-small-cell lung cancer received UFT (400 mg/m2 orally on days 1 through 52) and cisplatin (80 mg/m2 intravenously on days 8, 29, and 50). Radiotherapy, with a total dose of 60.8 Gy, was delivered in 38 fractions on days 1 through 52. Among the 17 patients entered, 16 experienced partial responses (94%; 95% confidence interval, 83% to 100%). The median time to tumor progression was 30 weeks (range, 8 to 87 weeks), and the 1-year survival rate was 80%. Hematologic toxicity was moderate. Grade 3 leukopenia occurred in 10 patients (59%), but no grade 4 hematologic toxicity was observed. No grades 3 or 4 nonhematologic toxicities were reported. These observations suggest that oral UFT plus cisplatin with concurrent radiotherapy can be safely administered to patients with locally advanced non-small-cell lung cancer. The demonstrated antitumor activity is high, making this combined-modality treatment worthy of further investigation in a multi-institution trial.

• Authors: Y Ichinose, T Yano, H Asoh, H Yokoyama, R Maruyama, C Ushijima, T Uehara, T Kanematsu, T Yohena, S Wada
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 13 Issue 7 Suppl 3 Pg. 98-101 (Jul 1999) ISSN: 0890-9091 [Print] United States
• PMID: 10442374 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Tegafur
• Uracil
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology, radiotherapy)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Female
• Follow-Up Studies
• Humans
• Lung Neoplasms (drug therapy, pathology, radiotherapy)
• Male
• Middle Aged
• Neoplasm Staging
• Retrospective Studies
• Tegafur (administration & dosage)
• Treatment Outcome
• Uracil (administration & dosage)